Cargando…

Oxidant/antioxidant imbalance is an inherent feature of depression

BACKGROUND: 50% to 60% of the people who have recovered from the first episode of depression experience a relapse. The immune system of the people suffering from depression is in a permanent state of pathological pro-inflammatory readiness. There are some reports that depressive episodes cause sensi...

Descripción completa

Detalles Bibliográficos
Autores principales: Talarowska, Monika, Szemraj, Janusz, Berk, Michael, Maes, Michael, Gałecki, Piotr
Formato: Online Artículo Texto
Lenguaje:English
Publicado: BioMed Central 2015
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4392866/
https://www.ncbi.nlm.nih.gov/pubmed/25880127
http://dx.doi.org/10.1186/s12888-015-0454-5
_version_ 1782366058222452736
author Talarowska, Monika
Szemraj, Janusz
Berk, Michael
Maes, Michael
Gałecki, Piotr
author_facet Talarowska, Monika
Szemraj, Janusz
Berk, Michael
Maes, Michael
Gałecki, Piotr
author_sort Talarowska, Monika
collection PubMed
description BACKGROUND: 50% to 60% of the people who have recovered from the first episode of depression experience a relapse. The immune system of the people suffering from depression is in a permanent state of pathological pro-inflammatory readiness. There are some reports that depressive episodes cause sensitization of immune-inflammatory pathways and that staing of depression (e.g. number of depressive episodes) is correlated with immune-inflammatory markers. The main objective of the study was to delineate whether recurrent major depression (rDD) is characterized by alterations in selected immune-inflammatory biomarkers as compared with first episode of depression (ED-I), i.e. expression of mRNA and enzymatic activity of manganese superoxide dismutase (MnSOD, SOD-2), myeloperoxidase (MPO), inducible nitric oxide synthase (iNOS, NOS-2), and cyclooxygenase-2 (COX-2). METHODS: The study was carried out in a group of 131 patients: ED-I group – 42 patients, rDD group – 89 patients. Depression severity was assessed with the 17-item Hamilton Depression Rating Scale (HDRS). The number of depression episodes and the disease duration periods were recorded in each patient. For the patients, HDRS was administered at admission during the symptomatic phase, which would generally be either before or shortly after modification of the previous antidepressant drug regimen. Reassessment of the mental condition was conducted after 8 weeks of the pharmacological treatment also with the use of the HDRS scale. RESULTS: No significant statistical differences were found between the analysed groups as regards the intensity of depressive disorders. No differences in the expression of MnSOD, MPO, COX-2 and i-NOS genes on the level of both mRNA and protein were observed between both groups. No significant interrelation was noticed between the number of depression episodes experienced and the expression of selected genes on the mRNA level and protein level. CONCLUSIONS: There is no significant difference in MnSOD, MPO, COX-2 and i-NOS between patients with recurrent depressive disorders and those in a first episode of depression. These findings suggest that these enzymes are trait markers of depression and are not related to staging of depression.
format Online
Article
Text
id pubmed-4392866
institution National Center for Biotechnology Information
language English
publishDate 2015
publisher BioMed Central
record_format MEDLINE/PubMed
spelling pubmed-43928662015-04-11 Oxidant/antioxidant imbalance is an inherent feature of depression Talarowska, Monika Szemraj, Janusz Berk, Michael Maes, Michael Gałecki, Piotr BMC Psychiatry Research Article BACKGROUND: 50% to 60% of the people who have recovered from the first episode of depression experience a relapse. The immune system of the people suffering from depression is in a permanent state of pathological pro-inflammatory readiness. There are some reports that depressive episodes cause sensitization of immune-inflammatory pathways and that staing of depression (e.g. number of depressive episodes) is correlated with immune-inflammatory markers. The main objective of the study was to delineate whether recurrent major depression (rDD) is characterized by alterations in selected immune-inflammatory biomarkers as compared with first episode of depression (ED-I), i.e. expression of mRNA and enzymatic activity of manganese superoxide dismutase (MnSOD, SOD-2), myeloperoxidase (MPO), inducible nitric oxide synthase (iNOS, NOS-2), and cyclooxygenase-2 (COX-2). METHODS: The study was carried out in a group of 131 patients: ED-I group – 42 patients, rDD group – 89 patients. Depression severity was assessed with the 17-item Hamilton Depression Rating Scale (HDRS). The number of depression episodes and the disease duration periods were recorded in each patient. For the patients, HDRS was administered at admission during the symptomatic phase, which would generally be either before or shortly after modification of the previous antidepressant drug regimen. Reassessment of the mental condition was conducted after 8 weeks of the pharmacological treatment also with the use of the HDRS scale. RESULTS: No significant statistical differences were found between the analysed groups as regards the intensity of depressive disorders. No differences in the expression of MnSOD, MPO, COX-2 and i-NOS genes on the level of both mRNA and protein were observed between both groups. No significant interrelation was noticed between the number of depression episodes experienced and the expression of selected genes on the mRNA level and protein level. CONCLUSIONS: There is no significant difference in MnSOD, MPO, COX-2 and i-NOS between patients with recurrent depressive disorders and those in a first episode of depression. These findings suggest that these enzymes are trait markers of depression and are not related to staging of depression. BioMed Central 2015-04-08 /pmc/articles/PMC4392866/ /pubmed/25880127 http://dx.doi.org/10.1186/s12888-015-0454-5 Text en © Talarowska et al.; licensee BioMed Central. 2015 This article is published under license to BioMed Central Ltd. This is an Open Access article distributed under the terms of the Creative Commons Attribution License (http://creativecommons.org/licenses/by/4.0), which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly credited. The Creative Commons Public Domain Dedication waiver (http://creativecommons.org/publicdomain/zero/1.0/) applies to the data made available in this article, unless otherwise stated.
spellingShingle Research Article
Talarowska, Monika
Szemraj, Janusz
Berk, Michael
Maes, Michael
Gałecki, Piotr
Oxidant/antioxidant imbalance is an inherent feature of depression
title Oxidant/antioxidant imbalance is an inherent feature of depression
title_full Oxidant/antioxidant imbalance is an inherent feature of depression
title_fullStr Oxidant/antioxidant imbalance is an inherent feature of depression
title_full_unstemmed Oxidant/antioxidant imbalance is an inherent feature of depression
title_short Oxidant/antioxidant imbalance is an inherent feature of depression
title_sort oxidant/antioxidant imbalance is an inherent feature of depression
topic Research Article
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4392866/
https://www.ncbi.nlm.nih.gov/pubmed/25880127
http://dx.doi.org/10.1186/s12888-015-0454-5
work_keys_str_mv AT talarowskamonika oxidantantioxidantimbalanceisaninherentfeatureofdepression
AT szemrajjanusz oxidantantioxidantimbalanceisaninherentfeatureofdepression
AT berkmichael oxidantantioxidantimbalanceisaninherentfeatureofdepression
AT maesmichael oxidantantioxidantimbalanceisaninherentfeatureofdepression
AT gałeckipiotr oxidantantioxidantimbalanceisaninherentfeatureofdepression